PD-1T TILs as precision biomarker in NSCLC 29 2 a potential biomarker to preselect patients for treatment with PD-1 blockade. Particularly, the absence of PD-1T TILs in a tumor may signify the lack of a tumorreactive T cell population and hence identify patients that are unlikely to benefit. In this retrospective observational study we analyzed pretreatment samples from two independent cohorts of NSCLC patients treated with PD-1 blockade to (1) train and validate PD-1T TILs as a predictive biomarker, (2) explore whether certain sample characteristics such as sample type, sample location or time of sampling influence the predictive value of this biomarker, and (3) evaluate the potential for clinical implementation, by comparing and combining PD-1T TILs with other predictive markers such as PD-L1 and TLS.
RkJQdWJsaXNoZXIy MTk4NDMw